Guangdong Biolight Meditech Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jinyuan Yan

İcra Kurulu Başkanı

CN¥1.8m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	13.8yrs
CEO sahipliği	27.0%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	3.4yrs

Son yönetim güncellemeleri

Recent updates

Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) Shares Bounce 39% But Its Business Still Trails The Industry

Oct 08

Returns On Capital Signal Tricky Times Ahead For Guangdong Biolight Meditech (SZSE:300246)

Jun 07

Why Investors Shouldn't Be Surprised By Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) 30% Share Price Plunge

Jun 06

There's No Escaping Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) Muted Revenues Despite A 31% Share Price Rise

Mar 08

CEO

Jinyuan Yan (61 yo)

13.8yrs

Görev süresi

CN¥1,790,400

Tazminat

Mr. Jinyuan Yan has been a Director of Guangdong Biolight Meditech Co., Ltd since January 9, 2011 and serves as its Chairman and President.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jinyuan Yan	Chairman & President	13.8yrs	CN¥1.79m	27.03% CN¥ 521.1m
Jin Liang	VP & Director	10.9yrs	CN¥742.50k	0.058% CN¥ 1.1m
Wei Liao	VP & Director	1.9yrs	CN¥493.20k	0.0096% CN¥ 185.7k
Jundong Xue	Independent Director	3.3yrs	CN¥120.00k	Veri yok
Zhen Xin Yang	Independent Director	1.9yrs	CN¥120.00k	Veri yok
Dayuan Chen	Supervisor	9.5yrs	Veri yok	Veri yok
Daoguo Zhang	Supervisor	10.9yrs	Veri yok	Veri yok
Xiaoming Li	Director	4.5yrs	CN¥120.00k	Veri yok
Bo Chen	Employee Supervisor	3.4yrs	Veri yok	Veri yok
Wenpu Tang	Non-Independent Director	1.9yrs	CN¥717.60k	Veri yok
Maoliang Ran	Independent Director	1.9yrs	CN¥120.00k	Veri yok
Jian Chen	Director	1.2yrs	CN¥30.00k	Veri yok

3.4yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300246 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.4 yıldır).

Guangdong Biolight Meditech Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Guangdong Biolight Meditech Co., Ltd., Annual General Meeting, May 20, 2024

Guangdong Biolight Meditech Co., Ltd. Approves Executive Elections

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.043 loss per share (vs CN¥0.02 profit in 3Q 2023)

Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) Shares Bounce 39% But Its Business Still Trails The Industry

New major risk - Revenue and earnings growth

Guangdong Biolight Meditech Co., Ltd. to Report Q3, 2024 Results on Oct 28, 2024

Less than half of directors are independent

Guangdong Biolight Meditech Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Returns On Capital Signal Tricky Times Ahead For Guangdong Biolight Meditech (SZSE:300246)

Why Investors Shouldn't Be Surprised By Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) 30% Share Price Plunge

Guangdong Biolight Meditech Co., Ltd., Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: EPS: CN¥0.014 (vs CN¥0.10 in 1Q 2023)

Investor sentiment deteriorates as stock falls 20%

New minor risk - Share price stability

Guangdong Biolight Meditech Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

There's No Escaping Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) Muted Revenues Despite A 31% Share Price Rise

Investor sentiment improves as stock rises 22%

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 18%

Guangdong Biolight Meditech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

Third quarter 2023 earnings released: EPS: CN¥0.02 (vs CN¥0.012 in 3Q 2022)

Guangdong Biolight Meditech Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.026 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.084 in 1Q 2022)

Guangdong Biolight Meditech Co., Ltd. Approves Executive Elections

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.018 (vs CN¥0.11 in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.039 loss per share (vs CN¥0.19 profit in 2Q 2021)

Guangdong Biolight Meditech Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 11 July 2022

Guangdong Biolight Meditech Co., Ltd. Approves 2021 Profit Distribution Plan

Guangdong Biolight Meditech Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.51 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥1.37 in 2Q 2020)

Guangdong Biolight Meditech Co., Ltd. Approves 2020 Profit Distribution Plan

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.28 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.37 (vs CN¥0.44 in FY 2019)

New 90-day low: CN¥25.16

New 90-day low: CN¥26.39

New 90-day low: CN¥26.84

New 90-day low: CN¥28.41

New 90-day low: CN¥31.40

Third quarter earnings released

Guangdong Biolight Meditech Co., Ltd. (SZSE:300246) signed an agreement to acquire 51% stake in Suzhou Jun Kang Medical Technology Co., Ltd. from Suzhou Dayisi Equity Investment Partnership (Limited Partnership) for approximately CNY 120 million.

First half earnings released

Guangdong Biolight Meditech Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş